Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 292

1.

CRISPR/Cas9 mediated ELANE knockout enables neutrophilic maturation of primary hematopoietic stem and progenitor cells and induced pluripotent stem cells of severe congenital neutropenia patients.

Nasri M, Ritter M, Mir P, Dannenmann B, Aghaallaei N, Amend D, Makaryan V, Xu Y, Fletcher B, Bernhard R, Steiert I, Hahnel K, Berger J, Koch I, Sailer B, Hipp K, Zeidler C, Klimiankou M, Bajoghli B, Dale DC, Welte K, Skokowa J.

Haematologica. 2019 Jun 27. pii: haematol.2019.221804. doi: 10.3324/haematol.2019.221804. [Epub ahead of print]

2.

Editorial: Update in myeloid biology.

Dale DC.

Curr Opin Hematol. 2019 Jan;26(1):1-5. doi: 10.1097/MOH.0000000000000475. No abstract available.

PMID:
30451722
3.

Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor.

Dale DC, Bolyard AA, Marrero T, Kelley ML, Makaryan V, Tran E, Leung J, Boxer LA, Kishnani PS, Austin S, Wanner C, Ferrecchia IA, Khalaf D, Maze D, Kurtzberg J, Zeidler C, Welte K, Weinstein DA.

Curr Opin Hematol. 2019 Jan;26(1):16-21. doi: 10.1097/MOH.0000000000000474.

PMID:
30451720
4.

Neutropenia in Barth syndrome: characteristics, risks, and management.

Steward CG, Groves SJ, Taylor CT, Maisenbacher MK, Versluys B, Newbury-Ecob RA, Ozsahin H, Damin MK, Bowen VM, McCurdy KR, Mackey MC, Bolyard AA, Dale DC.

Curr Opin Hematol. 2019 Jan;26(1):6-15. doi: 10.1097/MOH.0000000000000472.

PMID:
30451719
5.

ELANE-Related Neutropenia.

Dale DC, Makaryan V.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
2002 Jun 17 [updated 2018 Aug 23].

6.

Cyclic thrombocytopenia with statistically significant neutrophil oscillations.

Langlois GP, Arnold DM, Potts J, Leber B, Dale DC, Mackey MC.

Clin Case Rep. 2018 May 31;6(7):1347-1352. doi: 10.1002/ccr3.1611. eCollection 2018 Jul.

7.

Analysis of Factors Associated With In-hospital Mortality in Lung Cancer Chemotherapy Patients With Neutropenia.

Cupp J, Culakova E, Poniewierski MS, Dale DC, Lyman GH, Crawford J.

Clin Lung Cancer. 2018 Mar;19(2):e163-e169. doi: 10.1016/j.cllc.2017.10.013. Epub 2017 Oct 28. Review.

PMID:
29233611
8.

Long-Term Effects of G-CSF Therapy in Cyclic Neutropenia.

Dale DC, Bolyard A, Marrero T, Makaryan V, Bonilla M, Link DC, Newburger P, Shimamura A, Boxer LA, Spiekerman C.

N Engl J Med. 2017 Dec 7;377(23):2290-2292. doi: 10.1056/NEJMc1709258. No abstract available.

9.

Somatic mutations and clonal hematopoiesis in congenital neutropenia.

Xia J, Miller CA, Baty J, Ramesh A, Jotte MRM, Fulton RS, Vogel TP, Cooper MA, Walkovich KJ, Makaryan V, Bolyard AA, Dinauer MC, Wilson DB, Vlachos A, Myers KC, Rothbaum RJ, Bertuch AA, Dale DC, Shimamura A, Boxer LA, Link DC.

Blood. 2018 Jan 25;131(4):408-416. doi: 10.1182/blood-2017-08-801985. Epub 2017 Nov 1.

10.

Editorial: myeloid biology issue 2018.

Dale DC.

Curr Opin Hematol. 2018 Jan;25(1):1-2. doi: 10.1097/MOH.0000000000000397. No abstract available.

PMID:
29049086
11.

A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.

Dale DC, Crawford J, Klippel Z, Reiner M, Osslund T, Fan E, Morrow PK, Allcott K, Lyman GH.

Support Care Cancer. 2018 Jan;26(1):7-20. doi: 10.1007/s00520-017-3854-x. Epub 2017 Sep 22. Review.

12.

Elastase inhibitors as potential therapies for ELANE-associated neutropenia.

Makaryan V, Kelley ML, Fletcher B, Bolyard AA, Aprikyan AA, Dale DC.

J Leukoc Biol. 2017 Oct;102(4):1143-1151. doi: 10.1189/jlb.5A1016-445R. Epub 2017 Jul 28.

13.

Severe congenital neutropenias.

Skokowa J, Dale DC, Touw IP, Zeidler C, Welte K.

Nat Rev Dis Primers. 2017 Jun 8;3:17032. doi: 10.1038/nrdp.2017.32. Review.

14.

How I manage children with neutropenia.

Dale DC.

Br J Haematol. 2017 Aug;178(3):351-363. doi: 10.1111/bjh.14677. Epub 2017 Apr 17. Review.

PMID:
28419427
15.

JULIUS KREVANS, MD: 1924 - 2015.

Dale DC.

Trans Am Clin Climatol Assoc. 2016;127:xcv-xcvii. No abstract available.

16.

An update on the diagnosis and treatment of chronic idiopathic neutropenia.

Dale DC, Bolyard AA.

Curr Opin Hematol. 2017 Jan;24(1):46-53. Review.

17.

Editorial for myeloid biology 2017.

Dale DC.

Curr Opin Hematol. 2017 Jan;24(1):1-2. No abstract available.

PMID:
27820737
18.

Editorial: The mysteries of the spleen.

Dale DC.

J Leukoc Biol. 2016 Aug;100(2):249-51. doi: 10.1189/jlb.4CE0216-088R. No abstract available.

PMID:
27481938
19.

Tracers for tracing neutrophils.

Dale DC.

Blood. 2016 Jun 30;127(26):3300-2. doi: 10.1182/blood-2016-05-716035. No abstract available.

20.

Association Between Absolute Neutrophil Count and Variation at TCIRG1: The NHLBI Exome Sequencing Project.

Rosenthal EA, Makaryan V, Burt AA, Crosslin DR, Kim DS, Smith JD, Nickerson DA, Reiner AP, Rich SS, Jackson RD, Ganesh SK, Polfus LM, Qi L, Dale DC; University of Washington, Center for Mendelian Genomics, Jarvik GP.

Genet Epidemiol. 2016 Sep;40(6):470-4. doi: 10.1002/gepi.21976. Epub 2016 May 27.

21.

How I diagnose and treat neutropenia.

Dale DC.

Curr Opin Hematol. 2016 Jan;23(1):1-4. doi: 10.1097/MOH.0000000000000208. Review.

22.

The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study.

Culakova E, Poniewierski MS, Wolff DA, Dale DC, Crawford J, Lyman GH.

Springerplus. 2015 Aug 6;4:396. doi: 10.1186/s40064-015-1165-6. eCollection 2015.

23.

Changing patterns of chemotherapy relative dose intensity and supportive care for aggressive B-cell non-Hodgkin lymphoma.

Lyman GH, Crawford J, Tomita D, Whittaker S, Dale DC.

Leuk Lymphoma. 2016 Feb;57(2):283-290. doi: 10.3109/10428194.2015.1045894. Epub 2015 Jul 7.

PMID:
25926064
24.

Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?

Lyman GH, Dale DC, Legg JC, Abella E, Morrow PK, Whittaker S, Crawford J.

Cancer Med. 2015 Aug;4(8):1153-60. doi: 10.1002/cam4.454. Epub 2015 Mar 23.

25.

CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.

Rennard SI, Dale DC, Donohue JF, Kanniess F, Magnussen H, Sutherland ER, Watz H, Lu S, Stryszak P, Rosenberg E, Staudinger H.

Am J Respir Crit Care Med. 2015 May 1;191(9):1001-11. doi: 10.1164/rccm.201405-0992OC.

PMID:
25695403
26.

The effects of the CXCR2 antagonist, MK-7123, on bone marrow functions in healthy subjects.

Hastrup N, Khalilieh S, Dale DC, Hanson LG, Magnusson P, Tzontcheva A, Tseng J, Huyck S, Rosenberg E, Krogsgaard K.

Cytokine. 2015 Apr;72(2):197-203. doi: 10.1016/j.cyto.2015.01.002. Epub 2015 Feb 4.

PMID:
25661195
27.

Use of granulocyte colony-stimulating factor during pregnancy in women with chronic neutropenia.

Boxer LA, Bolyard AA, Kelley ML, Marrero TM, Phan L, Bond JM, Newburger PE, Dale DC.

Obstet Gynecol. 2015 Jan;125(1):197-203. doi: 10.1097/AOG.0000000000000602.

28.

Intersections of hematology, immunology, dermatology and infectious diseases.

Dale DC.

Curr Opin Hematol. 2015 Jan;22(1):1-2. doi: 10.1097/MOH.0000000000000106. No abstract available.

PMID:
25469835
29.

The diversity of mutations and clinical outcomes for ELANE-associated neutropenia.

Makaryan V, Zeidler C, Bolyard AA, Skokowa J, Rodger E, Kelley ML, Boxer LA, Bonilla MA, Newburger PE, Shimamura A, Zhu B, Rosenberg PS, Link DC, Welte K, Dale DC.

Curr Opin Hematol. 2015 Jan;22(1):3-11. doi: 10.1097/MOH.0000000000000105. Review.

30.

Cancer chemotherapy treatment patterns and febrile neutropenia in the US Veterans Health Administration.

Wang L, Barron R, Baser O, Langeberg WJ, Dale DC.

Value Health. 2014 Sep;17(6):739-43. doi: 10.1016/j.jval.2014.06.009. Epub 2014 Jul 26.

31.

Understanding, treating and avoiding hematological disease: better medicine through mathematics?

Dale DC, Mackey MC.

Bull Math Biol. 2015 May;77(5):739-57. doi: 10.1007/s11538-014-9995-x. Epub 2014 Sep 12.

32.

TCIRG1-associated congenital neutropenia.

Makaryan V, Rosenthal EA, Bolyard AA, Kelley ML, Below JE, Bamshad MJ, Bofferding KM, Smith JD, Buckingham K, Boxer LA, Skokowa J, Welte K, Nickerson DA, Jarvik GP, Dale DC; UW Center for Mendelian Genomics.

Hum Mutat. 2014 Jul;35(7):824-7. doi: 10.1002/humu.22563. Epub 2014 May 21.

33.

Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study.

Culakova E, Thota R, Poniewierski MS, Kuderer NM, Wogu AF, Dale DC, Crawford J, Lyman GH.

Cancer Med. 2014 Apr;3(2):434-44. doi: 10.1002/cam4.200. Epub 2014 Feb 17.

34.

Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis.

Skokowa J, Steinemann D, Katsman-Kuipers JE, Zeidler C, Klimenkova O, Klimiankou M, Unalan M, Kandabarau S, Makaryan V, Beekman R, Behrens K, Stocking C, Obenauer J, Schnittger S, Kohlmann A, Valkhof MG, Hoogenboezem R, Göhring G, Reinhardt D, Schlegelberger B, Stanulla M, Vandenberghe P, Donadieu J, Zwaan CM, Touw IP, van den Heuvel-Eibrink MM, Dale DC, Welte K.

Blood. 2014 Apr 3;123(14):2229-37. doi: 10.1182/blood-2013-11-538025. Epub 2014 Feb 12.

35.

Authors' reply.

Kumar S, Moorthy N, Yadav S, Kapoor A, Dale DC.

J Postgrad Med. 2013 Oct-Dec;59(4):340-1. No abstract available.

PMID:
24490312
36.

Risk factors for in-hospital mortality and prolonged length of stay in older patients with solid tumor malignancies.

Shayne M, Culakova E, Poniewierski MS, Dale DC, Crawford J, Wogu AF, Lyman GH.

J Geriatr Oncol. 2013 Oct;4(4):310-8. doi: 10.1016/j.jgo.2013.05.005. Epub 2013 Jun 28.

PMID:
24472473
37.

Variable clinical presentation of Shwachman-Diamond syndrome: update from the North American Shwachman-Diamond Syndrome Registry.

Myers KC, Bolyard AA, Otto B, Wong TE, Jones AT, Harris RE, Davies SM, Dale DC, Shimamura A.

J Pediatr. 2014 Apr;164(4):866-70. doi: 10.1016/j.jpeds.2013.11.039. Epub 2013 Dec 31.

38.

Understanding neutropenia.

Dale DC.

Curr Opin Hematol. 2014 Jan;21(1):1-2. doi: 10.1097/MOH.0000000000000012. No abstract available.

PMID:
24275692
39.

Thyroid storm presenting as congestive heart failure and protein-S deficiency-induced biventricular and internal jugular venous thrombii.

Kumar S, Moorthy N, Yadav S, Kapoor A, Dale DC.

J Postgrad Med. 2013 Jul-Sep;59(3):229-31. doi: 10.4103/0022-3859.118047.

40.

Evaluation and management of patients with isolated neutropenia.

Newburger PE, Dale DC.

Semin Hematol. 2013 Jul;50(3):198-206. doi: 10.1053/j.seminhematol.2013.06.010. Review.

41.

The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials.

Lyman GH, Dale DC, Culakova E, Poniewierski MS, Wolff DA, Kuderer NM, Huang M, Crawford J.

Ann Oncol. 2013 Oct;24(10):2475-84. doi: 10.1093/annonc/mdt226. Epub 2013 Jun 20. Review.

42.

A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.

Lyman GH, Dale DC, Tomita D, Whittaker S, Crawford J.

Breast Cancer Res Treat. 2013 Jun;139(3):863-72. doi: 10.1007/s10549-013-2582-2. Epub 2013 Jun 16.

PMID:
23771731
43.

Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer.

Hanna RK, Poniewierski MS, Laskey RA, Lopez MA, Shafer A, Van Le L, Crawford J, Dale DC, Gehrig PA, Secord AA, Havrilesky LJ, Lyman GH.

Gynecol Oncol. 2013 Apr;129(1):74-80. doi: 10.1016/j.ygyno.2012.12.017. Epub 2012 Dec 21.

PMID:
23262376
44.

Improving care of patients with immunodeficiency diseases.

Dale DC.

Curr Opin Hematol. 2013 Jan;20(1):1-2. doi: 10.1097/MOH.0b013e32835b06d5. No abstract available.

45.

Repeated lentivirus-mediated granulocyte colony-stimulating factor administration to treat canine cyclic neutropenia.

Yanay O, Dale DC, Osborne WR.

Hum Gene Ther. 2012 Nov;23(11):1136-43. doi: 10.1089/hum.2012.045. Epub 2012 Sep 12.

46.

Do G-CSF schedules make a difference?

Dale DC.

Am J Clin Oncol. 2012 Jun;35(3):307. doi: 10.1097/COC.0b013e31823a53e7. No abstract available.

PMID:
22609734
47.

Cyclic and chronic neutropenia: an update on diagnosis and treatment.

Dale DC.

Clin Adv Hematol Oncol. 2011 Nov;9(11):868-9. No abstract available.

PMID:
22252620
48.

Guidelines for pediatric management of severe chronic neutropenia.

Dale DC, Boxer LA.

Am J Hematol. 2012 Feb;87(2):133. doi: 10.1002/ajh.23107. Epub 2012 Jan 11. No abstract available.

49.

Twenty years of the colony-stimulating factors.

Dale DC.

Curr Opin Hematol. 2012 Jan;19(1):1-2. doi: 10.1097/MOH.0b013e32834e3c6e. No abstract available.

PMID:
22143076
50.

The cellular and molecular mechanisms for neutropenia in Barth syndrome.

Makaryan V, Kulik W, Vaz FM, Allen C, Dror Y, Dale DC, Aprikyan AA.

Eur J Haematol. 2012 Mar;88(3):195-209. doi: 10.1111/j.1600-0609.2011.01725.x. Epub 2011 Dec 4.

Supplemental Content

Support Center